Evidence map›Paper›PMID 30306086›Full record

ReviewBioMed research international2018

The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention.

Olga Di Fede, Vera Panzarella, Rodolfo Mauceri, Vittorio Fusco, Alberto Bedogni, Lorenzo Lo Muzio, Sipmo Onj Board, Giuseppina Campisi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Olga Di FedeDepartment of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.ORCID 0000-0002-5562-7420
Vera PanzarellaDepartment of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.ORCID 0000-0001-6339-6020
Rodolfo MauceriDepartment of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.ORCID 0000-0002-4008-6502
Vittorio FuscoOncology Unit, SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy.
Alberto BedogniUnit of Maxillofacial Surgery, Department of Neurosciences (DNS), University of Padua, Padua, Italy.
Lorenzo Lo MuzioDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.ORCID 0000-0003-4633-4893
Sipmo Onj BoardItalian Society of Oral Pathology and Medicine (SIPMO), Foggia, Italy.
Giuseppina CampisiDepartment of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.ORCID 0000-0002-9443-0495

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of antiresorptive and antiangiogenic agents; it is a potentially painful and debilitating condition that can considerably affect the quality of life of patients. Furthermore, even if its epidemiology and pathogenesis have still not been fully clarified, several risk factors related to MRONJ have been recognized in prevention protocols. Three main risk factors are as follows: (i) the type of ONJ-related medications: antiresorptive (e.g., Bisphosphonates, Denosumab) and antiangiogenic drugs (e.g., Bevacizumab, Sunitinib); (ii) the category of patient at MRONJ risk: cancer versus non-cancer patient; (iii) the typologies and timing of dental treatments (e.g., before, during, or after the drug administration). The aim of this paper is to describe the new paradigm by the Italian Society of Oral Pathology and Medicine (SIPMO) on preventive dental management in patients at risk of MRONJ, prior to and during/after the administration of the aforementioned ONJ-related drugs. In reducing the risk of MRONJ, dentists and oral hygienists are key figures in applying a correct protocol of primary prevention for pre-treatment and in-treatment patients. However, the necessity of a multidisciplinary standardized approach, with a sustained dialogue among specialists involved, should be always adopted in order to improve the efficacy of preventive strategies and to ameliorate the patient's quality of life.

Indexed as

Bisphosphonate-Associated Osteonecrosis of the JawAngiogenesis InhibitorsBone Density Conservation AgentsDiphosphonatesHumansNeoplasmsOsteoporosisAngiogenesis InhibitorsBone Density Conservation AgentsDiphosphonates

Identifiers

PMID30306086
PMCPMC6164200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.